Siga Technologies Inc.

Viropharma Incorporated

Sterling Winthrop Inc.

Cephalon, Inc.

Sanofi

Wyeth

Sterling Drug Inc.

Sanofi Sa

Sophrosyne Pharmaceuticals Limited

The Children's Hospital of Philadelphia

Kineta, Inc.

Teva Sante

Kineta Four, LLC

Sanofi Pharmaceuticals, Inc.

Thomas R Bailey

Guy D Diana

Theodore John Nitz

David J Aldous

Dongcheng Dai

Susan R Rippin

Robert Jordan

Gee-Hong Kuo

Edward R Bacon

Greg A Hostetler

Dorothy C Young

Robert L Hudkins

Dennis E Hruby

Yijun Deng

Tove C Bolken

Nadine C Becknell

Derek D Dunn

William P Gorczyca

Sankar Chatterjee

Allison L Zulli

Christopher J Burns

Hao Feng

Kurt A Josef

Ming Tao

Sean M Amberg

Diane E Gingrich

Keith S Learn

Ashis Kumar Saha

Sylvie Laquerre

David J Rys

Thomas A Lessen

Babu G Sundar

Jason C Wagner

Lars J S Knutsen

Thomas Faitg

Tom Leyssens

Alfred Michael Del Vecchio

John Swestock

Akram Sabouni

Lewis Feldberg

Vincent Wing-Fai Tai

Jason A Reinhardt

Bheemashankar A Kulkarni

Charles W Blackledge

Michael Reuman

Joseph M Salvino

Rabindranath Tripathy

George C Morton

Jonathan David Bloom

Richard Alan Couch

Brigitte Lesur

Christophe Yue

Bram Harmsen

Tové C Bolken

Gerard C Rosse

Yuanming Zhang

Martin Appelmans

Michael Paul Rene Guillot

Yanming Zhang

Robert J McHugh

Provided herein are novel crystalline forms of a compound that acts as an ALDH2 effector, processes for preparing the crystalline forms of the compound with or without coformer, and uses thereof.

Crystalline forms of ALDH2 modulators

The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and/or methods for treating and/or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and/or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.

Compounds and methods for treating alcohol disorder

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

Solid forms of fasoracetam

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

[object Object]

Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases

This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.

Tricyclic derivatives and their pharmaceutical use and compositions

The present invention is directed to methods of treating disorders mediated by Histamine Hreceptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine Hreceptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses

The present invention provides compounds of formula I: their use as Hantagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.

The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine Hreceptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

Aryl pyridazinone derivatives and their use as H3 receptor ligands

Growing community of inventors

Phoenixville, PA, United States of America

Thomas R Bailey